Positive Development in NICE Cabozantinib Appraisal Appeal

Positive Development in NICE Cabozantinib Appraisal Appeal

Neuroendocrine Cancer UK welcomes the outcome of the recent appeal relating to NICE’s appraisal of cabozantinib for advanced neuroendocrine tumours.  The NICE appeal panel has upheld three key appeal points while dismissing the remaining grounds of appeal. As a...
Advocacy & Policy Updates

Advocacy & Policy Updates

Advocacy & Policy Neuroendocrine Cancer UK was founded with the vision of providing support, raising awareness, and driving research for those affected by neuroendocrine cancer. What started as a small community initiative has now grown into a leading charity that...
NICE user involvement: NICE Prioritisation Board

NICE user involvement: NICE Prioritisation Board

The National Institute for Health and Care Excellence (NICE) set up the NICE Prioritisation Board to help decide topics for guidance development see more information. NICE are looking for two people to join the board to bring a perspective of patients, people who use...
Merkel Cell Carcinoma (MCC) Skin Cancer

Merkel Cell Carcinoma (MCC) Skin Cancer

Neuroendocrine Cancer UK is supporting Skin Cancer Awareness Month. Merkel cell carcinoma (MCC) is a rare, highly aggressive skin cancer, primarily affecting older patients, and thought to arise from the cutaneous Merkel cell, a neuroendocrine cell. The exact cause of...
Merkel Cell Carcinoma (MCC) Skin Cancer

Merkel Cell Carcinoma (MCC)

Neuroendocrine Cancer UK is supporting Skin Cancer Awareness Month.   Merkel cell carcinoma (MCC) is a rare, highly aggressive skin cancer, primarily affecting older patients, and thought to arise from the cutaneous Merkel cell, a neuroendocrine cell. The exact cause...

Unfortunately we are having to close our Helpline on Tuesday 6th October - however it will be open as usual on both Wednesday 7th and Thursday 8th.

X